|
Indications and Dosage
Oral
Susceptible infections Adult: 600 mg daily as a single or in 2 divided doses for 5-10 days.
Child: ≥6 mth 14 mg/kg daily as a single or in 2 divided doses. Max: 600 mg daily. |
||||
|
Renal Impairment
|
||||
|
Administration
May be taken with or without food.
|
||||
|
Reconstitution
Reconstitute powd for oral susp at the time of dispensing by adding the amount of water specified on the container to provide a susp containing 125 mg or 250 mg per 5 mL. Add water in 2 equal parts, invert and shake the bottle after each addition.
|
||||
|
Contraindications
Hypersensitivity to cefdinir or other cephalosporins.
|
||||
|
Special Precautions
Patient w/ history of penicillin allergy and colitis. Renal impairment. Childn. Pregnancy and lactation.
|
||||
|
Adverse Reactions
Diarrhoea, nausea, abdominal pain, vomiting, headache, skin rash, vulvovaginal candidiasis, proteinuria, elevated urine leukocytes, lymphocytosis, decreased serum bicarbonate, increased serum ALT and urine specific gravity.
Potentially Fatal: Anaphylaxis, Clostridium difficile-associated diarrhoea and colitis. |
||||
|
Monitoring Parameters
Monitor renal function; observe for signs and symptoms of anaphylaxis during 1st dose.
|
||||
|
Overdosage
Symptoms: Nausea, vomiting, epigastric distress, diarrhoea, convulsions. Management: Haemodialysis may be useful in the event of a serious toxic reaction particularly if renal function is compromised.
|
||||
|
Drug Interactions
Concomitant admin w/ antacids or Fe supplements reduce the rate and extent of absorption. Admin w/ Fe supplements may cause reddish stools. Decreased renal elimination w/ probenecid.
|
||||
|
Lab Interference
False-positive reaction for urinary ketones may occur w/ nitroprusside-based tests. False-positive urine glucose results may occur when using Clinitest®, Benedict's or Fehling's soln. May cause positive direct Coombs' test.
|
||||
|
Action
Description:
Mechanism of Action: Cefdinir binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Pharmacokinetics: Absorption: Absorbed from the GI tract. Bioavailability: Approx 16-25%. Time to peak plasma concentration: 2-4 hr. Distribution: Widely distributed into body tissues. Volume of distribution: 0.35 L/kg. Plasma protein binding: 60-70%. Metabolism: Minimal metabolism. Excretion: Via urine (approx 12-18% as unchanged drug). Elimination half-life: 1.7 hr. |
||||
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Database. Cefdinir, CID=6398970, https://pubchem.ncbi.nlm.nih.gov/compound/Cefdinir (accessed on Jan. 21, 2020) |
||||
|
Storage
Store between 20-25°C.
|
||||
|
MIMS Class
|
||||
|
References
Anon. Cefdinir. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/11/2014. Buckingham R (ed). Cefdinir. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/11/2014. Cefdinir capsule (Aurobindo Pharma Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/11/2014. Cefdinir Powder for Suspension (Lupin Pharmaceuticals Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/11/2014. McEvoy GK, Snow EK, Miller J et al (eds). Cefdinir. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 04/11/2014.
|
Sign Out
